Not All Immune Checkpoints Are Created Equal

Not All Immune Checkpoints Are Created Equal

Antibodies that block T cell inhibition via the immune checkpoints CTLA-4 and PD-1 have revolutionized cancer therapy during the last 15 years. T cells express additional inhibitory surface receptors that are considered to have potential as targets in cancer immunotherapy. Antibodies against LAG-3 a...

Full description

Bibliographic Details
Main Authors: Annika De Sousa Linhares, Judith Leitner, Katharina Grabmeier-Pfistershammer, Peter Steinberger
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
inhibitory receptors
immune checkpoints
PD-1
BTLA
LAG-3
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01909/full

Similar Items

Similar Items